SMARTERscreen 方案:一项三臂整群随机对照试验,评估全科诊所短信提醒对提高澳大利亚国家肠癌筛查项目参与率的作用
SMARTERscreen 是一项在澳大利亚两州63家全科诊所开展的三臂整群随机对照试验,纳入49-60岁即将收到国家肠癌筛查项目(NBCSP)检测包的患者。诊所等比例随机分为三组:仅发送鼓励性短信、发送短信加动机与指导视频链接、常规照护,主要比较6个月内NBCSP参与率的组间差异。
要点
- 既往SMARTscreen试验显示,筛查前发送含视频链接短信使参与率绝对提高16.5%(95%CI 2.02-30.9%)。
- 本试验将63家全科诊所等比例随机分为三组(21:21:21),预计每家诊所平均260名患者。
- 主要分析采用意向性治疗原则,比较6个月内NBCSP参与率的三个两两组间差异。
核心结论
- SMARTERscreen将提供高级别证据,确定在收到NBCSP检测包前向全科诊所患者发送短信或短信加网络材料是否能提高肠癌筛查参与率。
研究设计与样本
- 三臂分层整群随机对照试验,涉及澳大利亚两州的63家全科诊所。
- 合格患者为49-60岁、在干预期间未来2周内将收到NBCSP检测包的患者。
- 全科诊所等比例随机分为三组(21:21:21),估计每家诊所平均260名患者。
主要发现
- 既往SMARTscreen efficacy试验显示,与常规照护相比,在收到NBCSP检测包前从全科诊所发送含动机与指导视频的短信,参与率绝对提高16.5%(95%CI 2.02-30.9%)。
- SMARTERscreen将评估仅发送短信或发送短信加网络视频材料对NBCSP参与率的影响。
- 将评估患者对干预的依从性。
- 研究结果将纳入Policy1-Bowel微观模拟模型,以估计干预的长期健康获益和成本效果。
关键数值与推荐
- 两个干预组分别为:来自全科诊所的鼓励性短信;相同短信加额外动机与指导视频的网络链接。
- 对照组接受常规照护。
- 主要分析采用意向性治疗原则,估计各组在检测包发送后6个月内NBCSP参与比例的两两差异,使用澳大利亚国家癌症筛查登记处(NCSR)的筛查数据。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Australia persistently has one of the highest rates of colorectal cancer (CRC) in the world. Australia's National Bowel Cancer Screening Program (NBCSP) sends a biennial Faecal Immunochemical Test (FIT)-the 'NBCSP kit'-to everyone eligible for the programme between 50 and 74 years old; however, participation in the programme is low, especially in the 50- to 60-year-old age group. Our previous efficacy trial ('SMARTscreen') demonstrated an absolute increase in uptake of 16.5% (95% confidence interval = 2.02-30.9%) for people sent an SMS with motivational and instructional videos, from their general practice prior to receiving their NBCSP kit, compared to those receiving usual care. Building on the strengths of the SMARTscreen trial and addressing limitations, the 'SMARTERscreen' trial will test the effect on participation in the NBCSP of sending either an SMS only or an SMS with online video material to general practice patients due to receive their NBCSP compared to 'usual care'. METHODS: SMARTERscreen is a three-arm stratified cluster randomised controlled trial involving 63 general practices in two states in Australia. Eligible patients are patients who are aged 49-60 years and due to receive their NBCSP kit within the next 2 weeks during the intervention period. General practices will be equally randomised to three trial arms (21:21:21, estimated average 260 patients/practice). The two interventions include (i) an SMS with an encouraging message from their general practice or (ii) the same SMS with weblinks to additional motivational and instructional videos. The control arm will receive 'usual care'. Using the intention-to-treat approach, primary analysis will estimate the three pair-wise between-arm differences in the proportion of eligible patients who participate in the NBCSP within 6 months of when their kit is sent, utilising screening data from the Australian National Cancer Screening Register (NCSR). Patient intervention adherence to the interventions will also be evaluated. Findings will be incorporated into the Policy1-Bowel microsimulation model to estimate the long-term health benefits and cost-effectiveness of the interventions. DISCUSSION: SMARTERscreen will provide high-level evidence determining whether an SMS or an SMS with web-based material sent to general practice patients prior to receiving their NBCSP kit increases participation in bowel cancer screening. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry ACTRN12623000036617. Registered on 13 January 2023. Trial URL: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=385119&isClinicalTrial=False.
引用
- McIntosh JG, Emery JD, Wood A, et al. SMARTERscreen protocol: a three-arm cluster randomised controlled trial of patient SMS messaging in general practice to increase participation in the Australian National Bowel Cancer Screening Program. Trials. 2023. PMID: 37957680. doi:10.1186/s13063-023-07756-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。